

## Study: ENGOT-ov76 / GLORIOSA

Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR $\alpha$ -high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA).

### MaNGO Sites:

Prov	City	Site	Principal Investigator	Active**
BS	Brescia	Spedali Civili	Germana Tognon	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella*	
GE	Genova	Ospedale San Martino	Serafina Mammoliti	
GE	Genova	Ospedali Galliera	Nicoletta Provinciali	
LC	Lecco	Ospedale Manzoni	Federica Villa	
LU	Lucca	Ospedale San Luca	Editta Baldini	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PC	Piacenza	Osp. Guglielmo da Saliceto	Rosa Porzio	
PR	Parma	AOU Parma	Angelica Sikokis	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	
RM	Roma	Ospedale Umberto I	Federica Tomao	

\* MaNGO Principal Investigator

\*\* submission to CA ongoing